The Study
Improving cardiovascular risk prediction in metabolic liver disease with a novel biomarker-enhanced model
This study found that when doctors use a new formula with extra liver tests, it does a better job guessing who might have a heart attack. But it doesn't prove the liver tests cause the heart attacks — it just helps spot people who are more likely to have them.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Doctors usually guess heart attack risk using age, blood pressure, and cholesterol. This study made a new guess tool that also uses liver health markers.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 549 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — the new tool better separates who is truly at high risk, helping doctors decide who needs more attention.
- 2The new tool (LIVER-ASCVD+) had a score of 0.68 for predicting heart attacks or strokes (old tool: 0.63) and 0.63 for predicting death (old tool: 0.54).
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Current Medical Research and Opinion
Year
2025
Authors
L. Hegstrom, Yestle Kim, Pete Vu, Tyler Wagner, Robert Gish
Related Content
Claims (4)
Doctors should evaluate overall metabolic health when assessing cardiovascular disease risk, rather than focusing only on single blood test results.
In people with MASH, a new risk model that combines liver biomarkers with standard heart disease risk factors predicts heart attacks and strokes more accurately than the current standard model, and also predicts death risk more accurately.
In patients with biopsy-confirmed MASH, the LIVER-ASCVD+ model identifies groups with higher and lower rates of heart attack, stroke, and death over 10 years, and these rates differ significantly from those predicted by standard risk models.
In people with MASH, a commonly used heart disease risk calculator accurately predicts heart attacks or strokes only moderately well (AUC 0.63) and predicts death even less accurately (AUC 0.54).
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.